Trends in Retention on Antiretroviral Therapy in National Programs in Low-Income and Middle-Income Countries

被引:50
|
作者
Tassie, Jean-Michel [1 ]
Baijal, Parijat
Vitoria, Marco A.
Alisalad, Abdikamal [2 ]
Crowley, Siobhan P.
Souteyrand, Yves
机构
[1] WHO, HTM HIV SIR, Dept HIV AIDS, 20 Ave Appia, CH-1211 Geneva 27, Switzerland
[2] WHO, Reg Off Africa, Brazzaville, Rep Congo
关键词
antiretroviral therapy; monitoring; national programs; retention; resource-limited settings; survival; SUB-SAHARAN AFRICA; MORTALITY; OUTCOMES;
D O I
10.1097/QAI.0b013e3181d73e1b
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To document regional and global trends for patients retained on antiretroviral therapy (ART) 12-48 months after treatment initiation, in low-income and middle-income countries. Methods: Data reported by national programs to WHO/UNICEF/UNAIDS in 2008 were aggregated to produce regional and global estimates. The proportion of patients on ART at 12, 24, 36, and 48 months is derived from cohort monitoring systems in ART dispensing facilities. Results: Of 149 countries, 70 (47%) reported on retention at 12 months, 54 (36%) at 24 months, 38 (26%) at 36 months, and 30 (20%) at 48 months. Regional and global trends showed that the majority of attrition from ART programs occurred within the first year and declined thereafter. Among countries in sub-Saharan Africa, retention on ART was estimated at 75.2% at 12 months, 66.8% at 24 months, and remained at a similar level up to 48 months. Conclusions: After high attrition in the first year, retention on ART tends to stabilize. In the literature, attrition in the first year was related to early mortality. Earlier presentation for diagnosis of HIV infection, timely screening, and access to ART are fundamental to reduce it. Countries need support in reporting on outcomes on ART.
引用
收藏
页码:437 / 441
页数:5
相关论文
共 50 条
  • [31] Management of neonatal jaundice in low-income and middle-income countries
    Erdeve, Omer
    BMJ PAEDIATRICS OPEN, 2020, 4 (01)
  • [32] Partnership to tackle HCV in low-income and middle-income countries
    Das, Manjulika
    LANCET ONCOLOGY, 2021, 22 (09): : 1218 - 1218
  • [33] Rotavirus vaccine protection in low-income and middle-income countries
    Ramakrishnan, Girija
    Ma, Jennie Z.
    Haque, Rashidul
    Petri, William A., Jr.
    LANCET INFECTIOUS DISEASES, 2019, 19 (07): : 673 - 674
  • [34] Financing the Response to HIV in Low-Income and Middle-Income Countries
    Izazola-Licea, Jose Antonio
    Wiegelmann, Jan
    Aran, Christian
    Guthrie, Teresa
    De Lay, Paul
    Avila-Figueroa, Carlos
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 52 : S119 - S126
  • [35] Professional medical associations in low-income and middle-income countries
    Azimova, Aigul
    Abdraimova, Aida
    Orozalieva, Gulzat
    Muratlieva, Elvira
    Heller, Olivia
    Loutan, Louis
    Beran, David
    LANCET GLOBAL HEALTH, 2016, 4 (09): : E606 - E607
  • [36] Restrictive migration policies in low-income and middle-income countries
    Vijayasingham, Lavanya
    Rhule, Emma
    Asgari-Jirhandeh, Nima
    Allotey, Pascale
    LANCET GLOBAL HEALTH, 2019, 7 (07): : E843 - E844
  • [37] Acute liver failure in low-income and middle-income countries
    Vento, Sandro
    Cainelli, Francesca
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (11): : 1035 - 1045
  • [38] Determinants of youth crime in low-income and middle-income countries
    Murray, Joseph
    Atilola, Olayinka
    LANCET CHILD & ADOLESCENT HEALTH, 2020, 4 (02): : 96 - 98
  • [39] Screening and diagnosis of HBV in low-income and middle-income countries
    Jean-Pierre Allain
    Ohene Opare-Sem
    Nature Reviews Gastroenterology & Hepatology, 2016, 13 : 643 - 653
  • [40] Prevention of underage drinking in low-income and middle-income countries
    Assanangkornchai, Sawitri
    Tanaree, Athip
    Wichaidit, Wit
    LANCET CHILD & ADOLESCENT HEALTH, 2018, 2 (06): : 382 - 384